Registration Details
The NC3Rs NAMs Network brings researchers, developers and industry and regulatory end-users together to accelerate the use of new approach methodologies*.
Our NAMs Network symposium aims to connect technology developers with industry end-users. We will share insights from first-hand experiences of the deployment of NAMs technologies and future opportunities to reduce the reliance on animal toxicity testing in human safety assessment. There will be presentations from NAMs experts, panel discussions, a brainstorming workshop and networking opportunities.
Registration details
Please note this event is exclusively for members of the NC3Rs NAMs Network. If you are interested in attending but are not currently a member, please join the Network before registering for the event.
Agenda
Welcome
| Time | Details |
|---|---|
| 09.30 – 10.00 | Registration and refreshments |
| 10.00 – 10.15 | Welcome and introduction Dr Deb Milligan, NC3Rs |
Session 1: Learnings from the deployment of NAMs technologies
Chaired by Dr Natalie Burden, NC3Rs.
| Time | Details |
|---|---|
| 10.15 – 10.30 | Determining outputs when measuring potential toxic effects of candidate therapeutics Dr Georgios Stroulios, STEMCELL Technologies |
| 10.30 – 10.45 | Validating NAMs for developmental toxicity testing: Current trends and future perspectives Dr Amer Jamalpoor, Toxys |
| 10.45 – 11.00 | iPSC-derived models of DILI: Challenges to acceptance Dr Chris Kirton, Definigen |
| 11.00 – 11.15 | Applications of 3D InsightTM co-culture models for a combined safety and efficacy assessment Ms Christine Schwenk, InSphero |
| 11.15 – 11.35 | Panel discussion with the speakers |
| 11.35 – 11.50 | Break |
Session 2: Applying NAMs in industry settings
Chaired by Dr Carl Westmoreland, independent.
| Time | Details |
|---|---|
| 11.50 – 12.10 | Applying NAMs in industry settings Dr Anthony Lynch, GSK |
| 12.10 – 12.30 | Implementation of advanced cell models for non-clinical safety assessment: Successes and opportunities Dr Rhiannon David, AstraZeneca |
| 12.30 – 12.50 | Translating new approach methodologies (NAMs) into practice: Centre role of a CRO Dr Chris Cooper, Labcorp |
| 12.50 – 13.10 | Panel discussion with the speakers |
| 13.10 – 14.00 | Lunch break |
Session 3: Identifying opportunities to increase the uptake of NAMs
| Time | Details |
|---|---|
| 14.00 – 15.15 | Workshop |
| 15.15 – 15.30 | Break |
| 15.30 – 15.45 | Discussion of outcomes |
Session 4: Get involved – NAMs initiatives and engagement opportunities
| Time | Details |
|---|---|
| 15.45 – 15.50 | UK Centre of Excellence on In-Silico Regulatory Science and Innovation (CEiRSI) Professor Alex Frangi |
| 15.50 – 15.55 | British Toxicology Society Skills Gap Initiative Dr Camilla Alexander-White |
| 15.55 – 16.00 | NC3Rs stakeholder survey: Facilitating the development and uptake of new approach methodologies in safety assessment Dr Natalie Burden |
Session 5: Networking
| Time | Details |
|---|---|
| 16.00 – 17.00 | Sponsored by Labcorp |
* We use the term new approach methodologies specifically to refer to full and partial replacement approaches for assessing chemical or drug toxicity. Learn more on our page on NAMs terminology.